Epstein-Barr virus antigen–major histocompatibility complex class I complex

The Epstein-Barr virus antigen–major histocompatibility complex class I complex is formed when peptides derived from EBV proteins are processed in infected cells and loaded onto MHC class I molecules within the endoplasmic reticulum. These complexes are then transported to the cell surface, enabling recognition by CD8+ T cells and activation of cytotoxic responses against infected cells. EBV has evolved multiple immune evasion mechanisms to impair this process, reducing the cell surface expression of these complexes, including the use of viral proteins such as BILF1 (a G protein-coupled receptor that downregulates MHC class I), EBNA1 (which reduces antigenic peptide production), BNLF2a (which inhibits the transporter associated with antigen processing, TAP), and EBV-encoded microRNAs (which downregulate TAP1 expression). This allows EBV to persist in its host despite ongoing immune surveillance. If the intention is to capture a traditional drug target, consider specifying one of the EBV-encoded immune evasion proteins (e.g., EBV BILF1 receptor). The "EBV antigen–MHC class I complex" itself is not a canonical therapeutic target by common drug-target conventions.

Other names

EBV–MHC class I complexEpstein-Barr virus antigen-MHC-I complexEBV peptide–MHC class I complex

There are no drugs targeting the complex. However, virus-encoded proteins like EBV BILF1, BNLF2a, and EBNA1 can interfere with the formation and presentation of such complexes, enabling immune evasion.